Hebei Newtherapy BIo-Pharma technology Co., Ltd. Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2018
NCT03550183
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Hebei Newtherapy BIo-Pharma technology Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1